Dr. Fergal HILL is co-inventor of the pro-immunogenic tags oligoDOM® (OVX313) in its first and second generation. He has published in prominent international journals and is the coauthor of more than 15 patents or patent applications. Prior experience: • CSO, IMAXIO (2000-2017) • Researcher, European Molecular Biology Laboratory, Heidelberg, Germany (1999-2000) • Researcher, Laboratory of …
Archives du type de publication : Team Showcase
Dr Nathalie Garcon, Pharm D, PhD
Dr. Nathalie Garçon has more than 30 years of expertise in vaccinology, from research to manufacturing, in particular immunology, adjuvant and formulation technologies Expertise: • 5 new innovation projects selected, with implementation path defined and milestone established for go/no go decision • Restructuration of North America RD, with downsizing from 4 to 2 sites, and …
Prof. Jeffrey Almond, PhD
Prof. Jeffrey Almond is a pre-eminent vaccinologist. He has more than 40 years of expertise in the field of vaccines and Influenza Expertise: • His scientific contributions include the first demonstration that a single gene can determine host range – a finding highly relevant to understanding evolution of new Influenza pandemic strains • Completion of …
Dr Thomas Joudinaud, MD
Thomas has broad experience in healthcare ranging from practicing medicine to research, development and commercialization of therapeutics. He is a Cardio-vascular Thoracic surgeon by training and have more than 10 years of strategy consulting experience specialized in healthcare. Today, Thomas is CEO of Ceres-Brain Therapeutics, a biotech company spin-off from the CEA, and specialized in …
Dr Christian Pradeyrol, MD
Dr PRADEYROL is the Executive Chairman and Founder of Pradeyrol Développement, a family office actively investing in new technologies. With participations in a dozen of Biotech companies in France and in the US, Pradeyrol Développement is highly interested in immunology and preventive medicines, in vaccines, drugs and diagnostics. Prior experience: • Chairman and CEO, IMAXIO …
Dr Frédéric Schynts, PhD
Frédéric is a scientist with Virology, Immunology and Vaccinology background, experienced in vaccine, cell and gene therapy development from R&D to clinical phase, Business Development and Company Development strategy. Continuous learning and training on the Managerial and Entrepreneurial aspect of the Biotech Industry. Prior experience: • Investment Manager, Noshaq (2020-Present) • Independent Consultant (Schynts Consulting, …
Dr Chris Martin, PhD
Chris has over 20 years of experience in the pharmaceutical and biotech sector. He is an accomplished company founder and Director who has successfully brought technology from the lab to regulatory approval and global markets. Prior experience: • Chairman of the Board, Tokamak Energy Ltd (2015-current) • Co-founder and CEO, ADC Therapeutics (2012 – 2022) …
Linda Lebon
Linda has more than 25 years of experience in developing and implementing regulatory strategy for EU and US for different types of products including biotech and various therapeutic area. Her knowledge of drug development and regulatory matters is enhanced by her understanding of the challenges with which pharmaceutical companies are confronted in their effort to …
Dr. Delphine Guyon-Gellin, DVM
Delphine has 15 years experience in vaccines business and strategy working as strategic consultant for leading pharmaceutical companies to help them solve their key challenges, along with an in-depth expertise in strategy for vaccines Prior experience: • Project leader, Boston Consulting Group, London (2014-2017) • Senior Consultant, Boston Consulting Group, Paris (2011-2014) • Junior Consultant, …
Dr Nicola Groth, MD
Nicola has 25 years of experience in vaccine development with considerable expertise in influenza vaccines. Through her various strategic positions in the industry, she has developed expertise throughout the vaccine lifecycle, including close and extensive interactions with regulatory agencies. Prior Experience: • Global Head of Safety Evaluation & Risk Management, GlaxoSmithKline (GSK) Vaccines, Siena (2015-2023) …